The generic drug industry — and by extension, patients across the United States — is being adversely impacted by what some are calling branded drug makers’ abuse of risk evaluation and mitigation strategies, or REMS.
Despite creating a detailed plan to speed up the rate at which generic drug applications are reviewed, experts say a backlog has developed at the Food and Drug Administration’s Office of Generic Drugs.
Despite a rocky start, the full rollout of health reform under the Affordable Care Act has already brought major benefits to the nation’s troubled health system and affordable coverage to millions of formerly uninsured or underinsured Americans, one of the Obama administration’s top health officials asserted recently.
“We have a system that needs fixing.” That comment on the state of the nation’s healthcare system, shared by physician and New York Times correspondent and senior writer Elisabeth Rosenthal, served as the springboard for a high-level summit on the future of health care in the United States. The event drew a who’s who of nationally known health experts, scientists and government officials.